Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD

NCT07173920

Status	RECRUITING
Phase	Not Applicable
Sponsor	Peking University Sixth Hospital
Enrollment	62 participants

Key Eligibility Criteria

Inclusion (1)

- (1) Age between 18 and 65 years; (2) Patients whose diagnosis is consistent with the tardive dyskinesia (TD) diagnostic criteria defined by the Schooler-Kane criteria, with a disease duration of at least 3 months before screening, and a history of treatment with dopamine receptor antagonists for at least 3 months (a minimum of 1 month for patients aged e 60 years); other diseases that may cause involuntary movements are excluded

Exclusion (1)

- \-

Locations (1 total)

Peking University Sixth Hosptial, Beijing, China